NCT02140606View on ClinicalTrials.gov

Phase I Trial to Investigate Cafusertib Hydrochloride in Combination With Low Dose Cytarabine in Chinese Patients With Acute Myeloid Leukaemia (AML)

PHASE1UnknownINTERVENTIONAL
Timeline

Start Date

May 31, 2014

Primary Completion Date

December 31, 2015

Conditions
Leukemia, Myeloid, Acute
Interventions
DRUG

Cafusertib Hydrochloride

Drug: Cafusertib Hydrochloride (d1 and 15) Cafusertib (d1 and 15 - one hour iv.v) Drug: Cytarabine Cytarabine 2 x 20 mg/d s.c. d1-15.

Trial Locations (1)

300020

RECRUITING

Hospital of Blood Diseases, Chinese Academy of Medical Sciences, Tianjin

Sponsors
All Listed Sponsors
lead

Jiangsu Hansoh Pharmaceutical Co., Ltd.

INDUSTRY

NCT02140606 - Phase I Trial to Investigate Cafusertib Hydrochloride in Combination With Low Dose Cytarabine in Chinese Patients With Acute Myeloid Leukaemia (AML) | Biotech Hunter | Biotech Hunter